Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.

Journal of clinical microbiology - 19 May 2021

Dhillon Sharonjit K, Oštrbenk Valenčak Anja, Xu Lan, Poljak Mario, Arbyn Marc

Abstract excerpt

Only clinically validated human papillomavirus (HPV) tests should be used in cervical cancer screening. VALGENT provides a framework to validate new HPV tests. In the VALGENT-3 study, the clinical accuracy of the recently launched Abbott Alinity m HR HPV assay (Alinity m) to detect cervical precancerous lesions was assessed against the standard comparator test (Hybrid Capture 2; HC2) and against two previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alphapapillomavirus
Share to Early Detection of Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Genotyping Techniques

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Sensitivity and Specificity

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33731413
DOI: 10.1128/JCM.00286-21
PMCID: PMC8316144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.PMID 33731413Read ↗

Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting.Semantic proximity Read ↗

Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.Semantic proximity Read ↗

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.Semantic proximity Read ↗

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT FrameworkSemantic proximity Read ↗

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.Semantic proximity Read ↗

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.Semantic proximity Read ↗

Clinical Performance of the Alinity m HR HPV Assay in a Large Urban Cervical Cancer Screening Program in the United StatesSemantic proximity Read ↗

Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.Semantic proximity Read ↗

Clinical Validation of the Abbott RealTi <i>m</i> e High Risk HPV Assay According to the Guidelines for Human Papillomavirus DNA Test Requirements for Cervical ScreeningSemantic proximity Read ↗

Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.